Stay updated with breaking news from Single Administration. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Homology Medicines Presents Details of Optimized HMI-103 Nuclease-Free Gene Editing Candidate Featuring Integrated Liver-Specific Promoter to Maximize Long-Term Expression - read this article along with other careers information, tips and advice on BioSpace
- Multiple Presentations Feature HMI-103 Phase 1 Investigational Therapy for PKU, Including Genome-Wide Integration Assays to Confirm No Off-Target Editing...
Tampa, Fla. (PRWEB) December 07, 2021 -- Psilera Inc. (“Psilera”), a Florida-based biotechnology company developing non-hallucinogenic derivatives of
Amolyt Pharma Amolyt Pharma to Present Preliminary Phase 1 Data on AZP-3601 for Hypoparathyroidism and Additional Preclinical Data on AZP-3404 at ENDO 2021 Amolyt Pharma to Present Preliminary Phase 1 Data on AZP-3601 for Hypoparathyroidism and Additional Preclinical Data on AZP-3404 at ENDO 2021 Four abstracts accepted as poster presentations for the Endocrine Society’s Annual Meeting LYON, France and NEWTON, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specializing in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced ...
(0) Four abstracts accepted as poster presentations for the Endocrine Society's Annual Meeting LYON, France and NEWTON, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specializing in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced that it will be presenting four abstracts at the Endocrine Society's Annual Meeting, ENDO 2021, being held virtually from March 20-23, 2021. Amolyt will present preliminary data from its Phase 1 clinical trial evaluating AZP-3601, a parathyroid hormone analog specifically designed for the treatm...